|
The use of liquid biopsy comprehensive genomic profiling to identify the molecular landscape of patients with metastatic colorectal cancer who are candidates for anti-EGFR rechallange therapy: Findings from the CAVE-2 GOIM trial. |
| |
|
Honoraria - Novartis; Pierre fabre |
Consulting or Advisory Role - Novartis |
Speakers' Bureau - Merck KGaA; MSD; Novartis; Takeda |
Travel, Accommodations, Expenses - Amgen; Novartis |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Pierre Fabre; SERVIER |
Speakers' Bureau - Merck KGaA |
Travel, Accommodations, Expenses - Novartis |
| |
|
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda |
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Rottapharm Biotech; SERVIER; Takeda |
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Rottapharm Biotech (Inst) |
Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre; Takeda Science Foundation |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Guardant Health |
Consulting or Advisory Role - Bayer; Pierre Fabre; SERVIER; Takeda |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Celgene; Dompé Farmaceutici; Merck Serono; MSD Oncology |
Travel, Accommodations, Expenses - Merck Serono; MSD Oncology; Roche |
| |
|
Consulting or Advisory Role - Amgen; Bayer; Merck; Merck Serono; Servier |
Speakers' Bureau - Astellas Pharma (Inst); servier |
| |
|
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Incyte; Ipsen; Janssen; Merck Serono; MSD; Novartis; Roche; SERVIER |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Incyte; Ipsen; Janssen; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; SERVIER |
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Roche |
| |
|
Consulting or Advisory Role - Amgen/Dompé; Merck Serono; SERVIER |
| |
|
Honoraria - Amgen; AstraZeneca; Merck KGaA |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Merck KGaA |
Travel, Accommodations, Expenses - Merck KGaA |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; Merck KGaA; Pierre Fabre; Roche; SERVIER |
Travel, Accommodations, Expenses - AstraZeneca; Pierre Fabre |
| |
|
Honoraria - MSD; Novartis; Pierre Fabre |
Consulting or Advisory Role - Amgen; Merck KGaA; MSD; Pierre Fabre; Sanofi |
Speakers' Bureau - Amgen; MSD; Novartis |
Travel, Accommodations, Expenses - Amgen; Novartis |
| |
|
Consulting or Advisory Role - Amgen; Bayer; Merck KGaA; Pfizer; Roche/Genentech |
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst); SERVIER (Inst); Symphogen (Inst) |
| |
|
No Relationships to Disclose |